103 related articles for article (PubMed ID: 9253807)
41. Bivalent direct thrombin inhibitors: hirudin and bivalirudin.
Warkentin TE
Best Pract Res Clin Haematol; 2004 Mar; 17(1):105-25. PubMed ID: 15171961
[TBL] [Abstract][Full Text] [Related]
42. Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries.
Kalinowski M; Alfke H; Bergen S; Klose KJ; Barry JJ; Wagner HJ
Radiology; 2001 Jun; 219(3):716-23. PubMed ID: 11376260
[TBL] [Abstract][Full Text] [Related]
43. Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits.
Ragosta M; Barry WL; Gimple LW; Gertz SD; McCoy KW; Stouffer GA; McNamara CA; Powers ER; Owens GK; Sarembock IJ
Circulation; 1996 Mar; 93(6):1194-200. PubMed ID: 8653841
[TBL] [Abstract][Full Text] [Related]
44. Reocclusion after thrombolysis: a problem solved by hirudin?
Rübsamen K; Eschenfelder V
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):97-100. PubMed ID: 1773004
[TBL] [Abstract][Full Text] [Related]
45. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
48. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
49. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
[TBL] [Abstract][Full Text] [Related]
50. Clinical utility of subcutaneous hirudins.
Deitcher SR
Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S27-31. PubMed ID: 14593980
[TBL] [Abstract][Full Text] [Related]
51. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke.
Christou I; Alexandrov AV; Burgin WS; Wojner AW; Felberg RA; Malkoff M; Grotta JC
Stroke; 2000 Aug; 31(8):1812-6. PubMed ID: 10926939
[TBL] [Abstract][Full Text] [Related]
52. [Antithrombotic effects of recombinant hirudin in mice and its mechanism].
Cao WL; Li J
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2018 Apr; 34(4):371-374. PubMed ID: 30788948
[TBL] [Abstract][Full Text] [Related]
53. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
Murray TG; Jaffe GJ; McKay BS; Han DP; Burke JM; Abrams GW
Refract Corneal Surg; 1992; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
[TBL] [Abstract][Full Text] [Related]
54. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin.
Syed S; Schuyler PD; Kulczycky M; Sheffield WP
Blood; 1997 May; 89(9):3243-52. PubMed ID: 9129029
[TBL] [Abstract][Full Text] [Related]
55. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Schneider J; Friderichs E; Günzler WA; Flohé L
Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686
[TBL] [Abstract][Full Text] [Related]
56. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Chen LY; Nichols WW; Saldeen TG; Mehta JL
J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
[TBL] [Abstract][Full Text] [Related]
57. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.
Reddrop C; Moldrich RX; Beart PM; Farso M; Liberatore GT; Howells DW; Petersen KU; Schleuning WD; Medcalf RL
Stroke; 2005 Jun; 36(6):1241-6. PubMed ID: 15879331
[TBL] [Abstract][Full Text] [Related]
58. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
[TBL] [Abstract][Full Text] [Related]
59. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
60. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
Gurewich V
Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
